Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $0.89 in the prior trading day, Lexaria Bioscience Corp (NASDAQ: LEXX) closed at $0.88, down -1.20%. In other words, the price has decreased by -$1.20 from its previous closing price. On the day, 0.57 million shares were traded. LEXX stock price reached its highest trading level at $0.91 during the session, while it also had its lowest trading level at $0.851.
Ratios:
Our goal is to gain a better understanding of LEXX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 3.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 29 ’25 when BUNKA CHRISTOPHER bought 15,600 shares for $0.92 per share. The transaction valued at 14,375 led to the insider holds 270,012 shares of the business.
BUNKA CHRISTOPHER bought 11,900 shares of LEXX for $10,866 on Jul 30 ’25. The Director now owns 281,912 shares after completing the transaction at $0.91 per share. On Jul 29 ’25, another insider, McKechnie William Edward, who serves as the Director of the company, bought 5,000 shares for $0.91 each. As a result, the insider paid 4,532 and bolstered with 18,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEXX now has a Market Capitalization of 19532072 and an Enterprise Value of 12294340. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.50 while its Price-to-Book (P/B) ratio in mrq is 3.08. Its current Enterprise Value per Revenue stands at 19.961 whereas that against EBITDA is -1.09.
Stock Price History:
The Beta on a monthly basis for LEXX is 0.71, which has changed by -0.715534 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, LEXX has reached a high of $3.39, while it has fallen to a 52-week low of $0.77. The 50-Day Moving Average of the stock is -10.95%, while the 200-Day Moving Average is calculated to be -32.87%.
Shares Statistics:
The stock has traded on average 525.56K shares per day over the past 3-months and 2363750 shares per day over the last 10 days, according to various share statistics. A total of 22.23M shares are outstanding, with a floating share count of 20.41M. Insiders hold about 8.19% of the company’s shares, while institutions hold 10.34% stake in the company. Shares short for LEXX as of 1757894400 were 431470 with a Short Ratio of 0.82, compared to 1755216000 on 543726. Therefore, it implies a Short% of Shares Outstanding of 431470 and a Short% of Float of 2.4500001.
Earnings Estimates
At present, 3.0 analysts are actively evaluating the performance of Lexaria Bioscience Corp (LEXX) in the stock market.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.16 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.68 and -$0.71 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.54, with 3.0 analysts recommending between -$0.39 and -$0.68.
Revenue Estimates
2 analysts predict $137k in revenue for. The current quarter. It ranges from a high estimate of $174k to a low estimate of $100k. As of. The current estimate, Lexaria Bioscience Corp’s year-ago sales were $84k
A total of 2 analysts have provided revenue estimates for LEXX’s current fiscal year. The highest revenue estimate was $706k, while the lowest revenue estimate was $632k, resulting in an average revenue estimate of $669k. In the same quarter a year ago, actual revenue was $464.28k
